Home Amgen

Amgen

Stay informed about the latest news about Amgen by subscribing to our newsletter.

Looking to expand your partner network? Build relationships with academic teams and biotechs.

What is Amgen best known for?

Amgen is a leading biotech company that specializes in the development and manufacturing of innovative therapies. Their key contributions to medicine include Epogen for treating anemia, Neulasta for reducing infection risks in chemotherapy, Enbrel for autoimmune diseases, and Prolia for osteoporosis.

Where is Amgen located?

Amgen has its headquarters located in Thousand Oaks, California, United States. The company has multiple offices and facilities worldwide, including in Europe, Asia, and other regions, to support its global operations and research activities.

Got a news story for us related to Amgen? Send it to us here.

Latest Posts

News and Trends 20 Jul 2023

Seven pharma companies form alliance to prepare for future pandemics

Seven pharmaceutical companies have established the INTREPID Alliance with the goal of accelerating progress in discovery and development of new antiviral treatments for future pandemics. The seven companies are AbbVie, Amgen, Gilead, Johnson & Johnson, Novartis, Roche and Takeda. The INTREPID alliance creation is in support of the 100 Days Mission, which seeks to have […]

July 20, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 17 Jan 2023

TTP spinout Cellular Origins to focus on cell and gene therapies

TTP plc, a technology and product development company, has announced the launch of Cellular Origins. Cellular Origins is a TTP spin-out, created to enable scalable, cost-effective and efficient manufacture of cell and gene therapies. Cellular Origins’ proprietary technology addresses the current barriers associated with the manufacture of advanced therapies that are in late-stage development, enabling […]

January 17, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 6 Dec 2022

Positive results from BioAge muscle atrophy trial

BioAge Labs, Inc. has announced positive phase 1b clinical data for BGE-105, a highly selective, potent, orally available small-molecule agonist of the apelin receptor APJ. BGE-105 treatment resulted in statistically significant prevention of muscle atrophy relative to placebo in healthy volunteers aged 65 or older after 10 days of strict bed rest. Muscle atrophy—loss of […]

December 6, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 4 Aug 2022

Deal worth $3.7B sealed as Amgen buys biopharma ChemoCentryx

A company producing drugs including TAVNEOS to treat autoimmune diseases, plus others dealing with inflammatory disorders and cancer has been bought by biopharmaceutical company, Amgen for $52 per share. ChemoCentryx and Amgen have entered a definitive agreement worth approximately $3.7 billion. Robert Bradway, chairman and chief executive officer at Amgen, said: “The acquisition of ChemoCentryx […]

August 4, 2022 - 3 minutesmins - By Liza Laws

News and Trends 9 Jan 2018

Biocartis and Amgen Shake Hands on Another Cancer Diagnostics Deal

Biocartis will use its expertise in molecular diagnostics to produce a companion diagnostic test for Amgen’s upcoming cancer drug. Biocartis has signed its second agreement with US pharma giant, Amgen, to develop a companion diagnostic to test the suitability of a drug for a specific patient. Both deals will make use of Biocartis’ Idylla platform, a fully automated […]

January 9, 2018 - 1 minutemin - By Alex Dale

immatics amgen fundraising cancer immunotherapy

News and Trends 4 Oct 2017

Amgen Joins €50M German Fundraising for T-Cell Receptor Cancer Immunotherapy

Immatics has completed a $58M (€50M) round with the participation of Amgen, not long after both companies signed a billion-dollar partnership. Immatics, a company based in Tübingen specialized in cancer immunotherapy, has announced that its Series E round has reached $58M (€50M). Existing investors including dievini Hopp Biotech, Wellington Partners, and AT Impf took part in the fundraising, which […]

October 4, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 9 May 2017

Scottish Shark Antibodies have caught Amgen’s Eye

Elasmogen and its partner Feldan Therapeutics have signed a research agreement with Amgen to develop shark-inspired antibodies delivered intracellularly. Elasmogen, based in Aberdeen, Scotland, develops soloMER‘s, which are the smallest naturally-occurring antibody binding domains. “They are remarkably stable,” Caroline Barelle told me this morning at BioTrinity in London. “They can survive extreme pH and temperatures […]

May 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 25 Apr 2017

Novartis Negotiates its Way into the US Migraine Market

Amgen and Novartis have expanded their collaboration for the co-development of their migraine drug, ensuring Novartis will get a chunk of the US revenues. After Novartis and Amgen recently completed their second Phase III study for their migraine drug erenumab, the companies have now reworked their commercial partnership. The two pharma giants teamed up back in 2015 to co-develop […]

April 25, 2017 - 2 minutesmins - By Melanie De Almeida

Patrick Baeuerle Successful German Biotech Leader

Interview 17 Apr 2017

Meet One of the Most Successful German Biotech Leaders Ever

Patrick Baeuerle is the German biotech leader I wanted to interview the most (besides Simon Moroney from MorphoSys, who came to our Meetup in Munich last week). Patrick has explored and succeeded in just about every area of life sciences, be it as a highly cited academic researcher, a professor at Freiburg University, head of drug […]

April 17, 2017 - 6 minutesmins - By Philip Hemme

Screenshot 2017 01 09 at 12.40.51 PM e1483962109441

News and Trends 9 Jan 2017

German Immuno-Oncology Biotech partners up with Biotech Giant Amgen

Immatics and Amgen have inked a deal to develop bispecific drug candidates for cancer that could reach over €1B in milestones. Immatics, an immuno-oncology biotech in Tübingen, Germany, has signed an agreement with biotech giant Amgen. Immatics will receive €28.5M ($30M) upfront and up to €475M ($500M) per program and Amgen will be responsible for clinical development, manufacturing and […]

January 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 27 Oct 2016

€36M Fundraising to Sequence the Genome of Ireland

Genomics Medicine Ireland (GMI) has raised €36M ($40M) in series A to sequence the genome of the Irish and use the info for the development of new drugs and diagnostics. Genomics Medicine Ireland (GMI) is committed to revolutionizing health care with whole-genome sequencing. The company just raised €36M ($40M) in Series A that will be used to […]

October 27, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 5 Oct 2016

€365M deal for a Danish ‘DNA barcode’ Drug Screening Platform

The giant Amgen has offered Nuevolution €365M to develop oncology and neuroscience drugs. The small Danish Biotech claims to count with an unprecedented drug discovery platform that can screen billions of compounds way faster and at a lower cost than the big players. Despite its small size, Nuevolution is experienced in collaborating with big Pharma like Merck, Novartis, […]

October 5, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

Swiss biotech going strong in 2024: 18 companies to put on your radar

The ABC of biotech startup funding

Approaches

Therapeutic areas

Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR

Special Olympics: How is biotechnology revolutionizing sports performance worldwide?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us